Minaxolone
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
|
|
| Synonyms | 1-[(1S,2S,4S,5S,7S,10S,11S,14S,15S,17R)-17-(dimethylamino)-4-ethoxy-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]ethan-1-one |
| CAS Number | 62571-87-3  |
| PubChem (CID) | 71960 |
| IUPHAR/BPS | 5478 |
| ChemSpider | 64967  |
| UNII | 737SKC73L0 |
| KEGG | D05041 |
| ChEMBL | CHEMBL2105209 |
| Chemical and physical data | |
| Formula | C25H43NO3 |
| Molar mass | 405.614 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Minaxolone (CCI-12923) is a neuroactive steroid which was developed as a general anesthetic but was withdrawn before registration due to toxicity seen with long-term administration in rats, and hence was never marketed.[1][2][3] It is a positive allosteric modulator of the GABAA receptor,[4] as well as, less potently, a positive allosteric modulator of the glycine receptor.[4][5]
See also[edit]
References[edit]
- ^ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1358–. ISBN 978-0-412-46630-4.
- ^ J. G. Bovill; Michael B. Howie (1999). Clinical Pharmacology for Anaesthetists. W.B. Saunders. ISBN 978-0-7020-2167-1.
- ^ Hugh C. Hemmings; Philip M. Hopkins (2006). Foundations of Anesthesia: Basic Sciences for Clinical Practice. Elsevier Health Sciences. pp. 305–. ISBN 0-323-03707-0.
- ^ a b Giovanni Biggio; Robert H. Purdy (2001). Neurosteroids and Brain Function. Academic Press. pp. 196–. ISBN 978-0-12-366846-2.
- ^ Weir CJ, Ling AT, Belelli D, Wildsmith JA, Peters JA, Lambert JJ (May 2004). "The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors". Br J Anaesth. 92 (5): 704–11. doi:10.1093/bja/aeh125. PMID 15033889.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
